Sales increased across GlaxoSmithKline’s three business groups in 2017, but the company expressed caution for the year ahead owing to uncertainty about the timing of the market entry of a generic competitor for its respiratory medicine Advair. ---Subscribe to MedNous to access this article--- Company News
